RAS blockers offer similar mortality benefits for black and non-black patients with HFrEF: JAMA
RAS blockers offer similar mortality benefits for blacks and non-black patients with HFrEF suggests a new study published in the JAMA. Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black …